BioSpace News Archive

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today financial results for the first quarter of 2023 and provided a corporate

Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions,” “INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for its fiscal third quarter ended March 31, 2023, and provided a business update.

Gamida Cell Ltd., a cell therapy pioneer working to turn cells into powerful therapeutics, announced that the company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to review its first quarter 2023 financial results and provide an update on the company.

Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL) today announced that clinical data from three studies in B-NHL, RRMM and B-ALL will be presented at the 2023 European Hematology Association (EHA) Annual Meeting taking place June 8-15 in Frankfurt, Germany, and online.

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced the promotion of Michael Sherman Blue, M.D., FACEP to the position of Chief Medical Officer, reporting directly to the Company’s Board of Directors.

Cyclerion Therapeutics, Inc. announced that it has signed a definitive agreement with a new private company to sell two of its sGC stimulator assets in exchange for cash and equity ownership.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced corporate updates and first quarter 2023 financial results.

Innoviva Specialty Therapeutics today announced that The Lancet Infectious Diseases published detailed results from the pivotal Phase 3 ATTACK trial of sulbactam-durlobactam, the first pathogen-targeted therapy being studied for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) today announced that the U.S. Food and Drug Administration’s (FDA) Pulmonary-Allergy Drug Advisory Committee (PADAC) voted 16:6 in favor for adults, and 17:5 in favor for children (<18 years of age and ≥30 kg).

An imported version of Nefecon delayed release capsule has been added to the 2023 New Reimbursement Drug List of Specialized Medicines of the “Beijing Puhui Health Insurance Program.” Nefecon is a first-in-disease treatment for adults with primary immunoglobulin A nephropathy.